Building a Diversified Product Portfolio Centered on T Cell
Grit Bio is focused on early discovery and commercialization of next-generation T-cell therapies. Centered on a range of T-cell therapies, including personalized therapies, functional enhancement, off-the-shelf approaches and in vivo engineering, the Company has built a diversified T-cell product portfolio spanning multiple technology fronts and therapeutic settings. Guided by key clinical needs in cancer immunotherapy and autoimmune diseases, Grit Bio is advancing tumor-infiltrating lymphocyte (TIL) therapies, off-the-shelf allogeneic cell therapies, in vivo CAR-T therapies and neoantigen cancer vaccines. Supported by the Company's proprietary platforms spanning target discovery, cell engineering, targeted in vivo delivery and scalable manufacturing, Grit Bio aims to facilitate T-cell therapies’ evolvement as a more efficient, more accessible and more precise treatment paradigm.
Explore Our Core ProductsTechnology Platforms
Integrated platforms spanning discovery, engineering, manufacturing and targeted delivery support the development of differentiated cell and gene therapies.
StemTexp® Stem-like TIL Expansion Technology Platform
- ●Proprietary process platform with global intellectual property protection
- ●Over 400 batches of TIL products developed and manufactured
- ●Manufacturing success rate ≥90%
- ●End products with enriched central memory T cells
StaViral® Stable Cell Line Technology Platform
- ●High-quality, low-cost GMP manufacturing of retroviral vectors
ImmuT Finder® Immunoregulatory Target Discovery Platform
- ●High-throughput screening of novel immune targets
- ●Identification of key immunoregulatory targets with the potential to overcome tumor microenvironment (TME) challenges
- ●Development of first-in-class products with favorable safety and efficacy
KOReTIL® High-Efficiency TIL Gene-Knockout System
- ●Knockout efficiency >90% in TIL drug products
- ●Parallel functional validation of multiple targets
NEOvigator® Neoantigen Discovery Platform
- ●Multidimensional, high-throughput screening
- ●Functional validation using autologous TILs and PBMCs
- ●Proprietary AI algorithms for optimized immunogenicity prediction
- ●10-fold neoantigen prediction accuracy of conventional methods
APC-Targeted LNP Delivery Technology
- ●Targeted delivery to APCs across multiple organs while minimizing off-target delivery to liver
- ●Potent antigen-specific T-cell responses at one-tenth the dose required with LPX
- ●Highly efficient and safe proprietary ionizable lipids supporting redosing
OptiDiff® Universal Cell Expansion Platform
- ●Universal CAR-iNKT cell differentiation and expansion platform
- ●10⁷-fold expansion over a five-week process
- ●Ultra-high purity ≥95%
- ●Cost-effective, large-scale manufacturing
T-Cell-Targeted LNP Delivery Technology
- ●Full freedom-to-operate platform based on proprietary ionizable lipids and conjugation technologies
- ●10-to-60-fold dose reduction enabled by ultra-efficient T-cell targeting
- ●Excellent safety profile with minimal expression in myeloid cells and the liver
- ●Significant manufacturing and cost advantage
TgVec® Viral Vector Delivery Platform
- ●AI-designed T-cell binders and proprietary fusogens for selective and efficient in vivo transduction
- ●Modular payload architecture supporting single- or dual-CAR constructs and functional enhancers across different indications
- ●High-titer, scalable manufacturing with consistent product quality
News Center
Follow the latest news and updates from Grit Bio.
